Fierce Biotech

  • As geopolitical tensions rise, Nkarta CEO Paul Hastings is urging the U.S. government not to impose restrictions on Chinese scientific collaboration and refocus on what matters most: the patient.

  • The trials demonstrated the benefits of Praxis' ulixacaltamide in essential tremor after a previously grim outlook at an interim analysis of one of the studies earlier this year.

  • French antibody specialist Adcytherix has added a €105 million ($122 million) series A to its coffers, which the Marseille-based biotech will use to push its lead antibody-drug conjugate into clinical trials.

  • The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.

  • Dianthus Therapeutics is offering Nanjing Leads Biolabs up to $1 billion biobucks for licensing rights to a bifunctional fusion protein designed to treat certain autoimmune disorders.

Main Menu